Overview

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

Status:
Not yet recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The goal of this intervention research is to learn about the safety and tolerability of 162 with a single ascending dose in subjects with chronic hepatitis B virus (HBV) infection.
Phase:
Phase 1
Details
Lead Sponsor:
Yangshengtang Co., Ltd